康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00867 康哲药业

已收盘 04-10 16:09:20

14.300

-0.090

-0.63%

最高14.530	最低14.060	成交量313.50万
今开14.380	昨收14.390	日振幅3.27%
总市值348.92亿	流通市值348.85亿	总股本24.40亿
成交额4,447万	换手率0.13%	流通股本24.40亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00867","market":"HK","secType":"STK","nameCN":"康哲药业","latestPrice":14.3,"timestamp":1775808560003,"preClose":14.39,"halted":0,"volume":3135000,"delay":0,"changeRate":-0.006254343293954125,"floatShares":2439528512,"shares":2440000000,"eps":0.7055794113730189,"marketStatus":"已收盘","change":-0.09,"latestTime":"04-10 16:09:20","open":14.38,"high":14.53,"low":14.06,"amount":44473490,"amplitude":0.032662,"askPrice":14.3,"askSize":42000,"bidPrice":14.25,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":0.7055794113730189,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":5,"adr":0,"listingDate":1285603200000,"exchange":"SEHK","adjPreClose":14.39,"dividendRate":0.020846,"openAndCloseTimeList":[[1775784600000,1775793600000],[1775797200000,1775808000000]],"volumeRatio":0.502174,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00867","defaultTab":"news","newsList":[{"id":"1177041520","title":"康哲药业2026年3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1177041520","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177041520?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:33","pubTimestamp":1774956788,"startTime":"0","endTime":"0","summary":"China Medical System Holdings Limited（康哲药业控股有限公司）于2026年3月31日发布截至2026年3月31日的股份变动月报表。公司（股票代码：00867）于报告期内未发生新增发行、购回或注销等变动，股本结构保持不变。\n公司普通股注册股本在本月首尾均为20,000,000,000股，面值每股0.005美元，总额维持在100,000,000美元。已发行股份数量同样保持在2,439,528,512股，并无库存股。\n公告显示，截至2026年3月31日，公司确认已遵守香港联交所《上市规则》及相关法律法规，并维持足够的公众持股量。\n本次公告由公司秘书吴三燕签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622837697","title":"【券商聚焦】招商证券维持康哲药业(00867)“强烈推荐”评级 指创新转型成效显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2622837697","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622837697?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:24","pubTimestamp":1774513494,"startTime":"0","endTime":"0","summary":"截至2026年3月，公司布局近50款创新产品，其中7款已在中国获批上市，约20个项目处于临床试验阶段。2026年1月和3月，磷酸芦可替尼乳膏白癜风适应症和德昔度司他片分别于中国获批上市。报告预计，目前处于NDA阶段的6款产品将陆续获批，持续充实商业化产品群。维持“强烈推荐”投资评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/MzdhOTliMTI0NzhlMTgxMzU2MzczNzM1NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/MzdhOTliMTI0NzhlMTgxMzU2MzczNzM1NA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977392","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06099","00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621743834","title":"康哲药业：创新药与独家药增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2621743834","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621743834?lang=zh_cn&edition=full","pubTime":"2026-03-23 00:16","pubTimestamp":1774196160,"startTime":"0","endTime":"0","summary":"近日，康哲药业控股有限公司（以下简称“康哲药业”）发布2025年度业绩公告，全面展现战略转型成效。财报显示，公司业绩已重回长周期增长轨道，创新药与独家药成为核心增长引擎，集采影响基本出清，叠加多款重磅新药密集获批与管线稳步推进，长期发展动能全面焕新。2025年是康哲药业战略转型的关键收获年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603233679834735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","IE00BMCWC346.EUR","IE00BGHQDM52.EUR","06978","IE00BVYPNQ40.USD","SG9999015945.SGD","BK1574","00867","BK1191","BK1593","SG9999015952.SGD","IE00BVYPNP33.GBP","SG9999004220.SGD","SG9999015978.USD","IE00BYV24P56.USD","159992","SG9999015986.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620218961","title":"大行评级丨里昂：上调康哲药业目标价至16.5港元，维持“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2620218961","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620218961?lang=zh_cn&edition=full","pubTime":"2026-03-19 11:27","pubTimestamp":1773890823,"startTime":"0","endTime":"0","summary":"里昂发表研报指，康哲药业去年下半年收入按年增长9%，但由于一次性税项，导致净利润下滑23%，符合市场预期。该行相信，公司已基本消化带量采购(VBP)的影响，且2026年将会由创新药带动新一轮盈利加速周期。康哲药业及其子公司Dermavon计划在2026至28年间推出多款创新药，相信可以支持公司2026至27年收入及盈利持续增长中双位数水平。该行预计公司2026至28年各年收入分别增长18%、19%及20%，净利润则升29%、23%及22%。以目标明年市盈率15倍计，该行将康哲药业目标价由15.6港元上调至16.5港元，维持“跑赢大市”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260319/32080839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186440891","title":"异动解读 | 大行齐上调目标价，康哲药业盘中大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186440891","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186440891?lang=zh_cn&edition=full","pubTime":"2026-03-18 13:45","pubTimestamp":1773812717,"startTime":"0","endTime":"0","summary":"康哲药业今日盘中大幅上涨5.09%，引起了市场的广泛关注。其中，中金公司发布报告称，考虑新品放量，上调康哲药业2026/2027年经调净利润预测6%及9%，并同步上调目标价6%至17.50港元，维持“跑赢行业”评级，报告指出其创新药和独家药品已成为核心增长引擎，战略转型成效彰显。与此同时，花旗银行也发布报告，维持康哲药业“买入”评级，并将目标价由16.6港元上调至17.5港元，以反映管理层对创新药快速增长的指引。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620285873","title":"大行评级丨花旗：上调康哲药业目标价至17.5港元，上调收入及每股盈利预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2620285873","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620285873?lang=zh_cn&edition=full","pubTime":"2026-03-18 11:07","pubTimestamp":1773803222,"startTime":"0","endTime":"0","summary":"花旗发表研报指，康哲药业2025年收入按年增长9.9%至82.12亿元，符合该行及市场预期；净利润按年下跌8.1%至14.89亿元，较该行及市场预期低12%及11%，主要由于与西藏药业相关的税务优惠被取消而产生一次性税务支出2.79亿元；撇除此因素，净利润应为17.75亿元，按年增长3.6%。根据管理层最新对创新药快速增长的指引，该行上调2026及2027年收入预测1%及4%，每股盈利预测上调1%及13%；目标价由16.6港元上调至17.5港元，以反映增长加速，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260318/32077494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620283264","title":"中金：维持康哲药业(00867)跑赢行业评级 上调目标价至17.50港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620283264","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620283264?lang=zh_cn&edition=full","pubTime":"2026-03-18 10:40","pubTimestamp":1773801618,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑新品放量，上调康哲药业2026/2027年经调净利润6%/9%至21.12亿元/26.35亿元。维持跑赢行业评级，同步上调目标价6%至17.50港元，对应18.0倍2026年市盈率和14.2倍2027年市盈率，隐含35%上行空间。中金主要观点如下：2025年业绩符合市场预期公司公布2025年业绩：收入82.12亿元，同比增长9.9%，经调整净利润17.76亿元，同比增长3.6%，符合市场预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619165464","title":"康哲药业(00867)公布2025年业绩 拥有人应占溢利约14.89亿元 同比减少8.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619165464","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619165464?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:52","pubTimestamp":1773672729,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 公布2025年业绩，营业额同比增长 9.95%至82.12亿元;公司拥有人应占溢利约14.89亿元，同比减少8.08%;每股基本盈利0.6154元，拟派末期股息每股0.1366 元。已上市创新药加速放量，逐步形成推广规模效应。回望2025年，康哲药业已实现里程碑式的战略突破。集团正以卓越的发展韧性与战略张力，稳步成长为一家根植中国、竞逐全球新兴市场的创新驱动型国际化医药企业，为全球医药健康事业创造长远价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015986.USD","IE00BMCWC346.EUR","00867","IE00BGHQDM52.EUR","IE00BYV24P56.USD","BK1593","SG9999015945.SGD","IE00BVYPNP33.GBP","SG9999015952.SGD","IE00BVYPNQ40.USD","BK1191","LU2488822045.USD","SG9999004220.SGD","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105156245","title":"康哲药业肾病贫血新药德司达他片获中国药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1105156245","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105156245?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:45","pubTimestamp":1773398712,"startTime":"0","endTime":"0","summary":"康哲药业宣布，其用于治疗肾病贫血的创新药物德司达他片已正式获得中国国家药品监督管理局的上市批准。这一重要进展标志着公司在肾脏疾病治疗领域取得了新的突破。\n德司达他片作为一种新型口服药物，其获批将为国内肾病贫血患者提供更便捷、有效的治疗选择。此次获批也进一步丰富了康哲药业在慢性肾病治疗领域的产品管线，有望为公司带来新的业绩增长点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015952.SGD","SG9999004220.SGD","BK1191","IE00BMCWC346.EUR","LU2488822045.USD","SG9999015978.USD","SG9999015986.USD","00867","IE00BVYPNQ40.USD","SG9999015945.SGD","IE00BVYPNP33.GBP","IE00BYV24P56.USD","BK1593","IE00BGHQDM52.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619119691","title":"康哲药业(00867)：肾性贫血新药德昔度司他片中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2619119691","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619119691?lang=zh_cn&edition=full","pubTime":"2026-03-13 18:44","pubTimestamp":1773398665,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 公布，肾性贫血新药德昔度司他片上市许可申请已于2026年3月13日获得中国国家药品监督管理局批准。CKD患者肾功能逐渐丧失，最终出现肾衰竭。如果肾功能受损，肾脏生成EPO水平下降或完全不生成EPO，从而导致贫血。产品中国III期临床试验取得了积极结果。扩展期研究结果显示，产品可使Hb水平长期维持在达标水平，且安全性良好。此外，产品还可以显著降低铁调素水平，纠正铁代谢紊乱。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康哲药业(00867)：肾性贫血新药德昔度司他片中国获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","IE00BYV24P56.USD","BK1593","00867","IE00BVYPNP33.GBP","IE00BVYPNQ40.USD","SG9999004220.SGD","LU2488822045.USD","SG9999015952.SGD","SG9999015986.USD","IE00BMCWC346.EUR","SG9999015978.USD","SG9999015945.SGD","IE00BGHQDM52.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618118235","title":"每日卖空追踪 | 康哲药业 03月12日卖空量成交19.3万股，卖空比例为5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618118235","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618118235?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:30","pubTimestamp":1773304216,"startTime":"0","endTime":"0","summary":"康哲药业北京时间03月12日，涨1.38%，卖空量成交19.3万股，较上一交易日减少38.34%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163145a4637240&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163145a4637240&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BGHQDM52.EUR","00867","IE00BYV24P56.USD","SG9999004220.SGD","SG9999015952.SGD","SG9999015978.USD","IE00BVYPNQ40.USD","IE00BVYPNP33.GBP","LU2488822045.USD","SG9999015986.USD","BK1593","SG9999015945.SGD","IE00BMCWC346.EUR","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618428246","title":"每日卖空追踪 | 康哲药业 03月09日卖空量成交31.4万股，卖空比例为5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618428246","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618428246?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:30","pubTimestamp":1773045016,"startTime":"0","endTime":"0","summary":"康哲药业北京时间03月09日，涨0.76%，卖空量成交31.4万股，较上一交易日减少41.96%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163144a6b1c516&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163144a6b1c516&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999015952.SGD","SG9999004220.SGD","BK1191","IE00BMCWC346.EUR","LU2488822045.USD","SG9999015978.USD","SG9999015986.USD","00867","IE00BVYPNQ40.USD","SG9999015945.SGD","IE00BVYPNP33.GBP","IE00BYV24P56.USD","BK1593","IE00BGHQDM52.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618764287","title":"康哲药业自研减重新药CMS-D008获批临床，创新机制开辟减重新路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2618764287","media":"药研界面","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618764287?lang=zh_cn&edition=full","pubTime":"2026-03-09 13:56","pubTimestamp":1773035790,"startTime":"0","endTime":"0","summary":"近日，康哲药业控股有限公司正式宣布，其自主研发的靶向INHBE的小干扰RNA药物CMS-D008注射液，成功获得国家药品监督管理局药品审评中心签发的新药临床试验批件，获批开展用于治疗超重或肥胖人群的临床试验。除了超重或肥胖这一核心适应症，康哲药业明确表示，未来CMS-D008还将进一步拓展适应症范围，有望覆盖腹型肥胖以及相关代谢性疾病，包括非酒精性脂肪性肝病、2型糖尿病等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091429419545c8cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091429419545c8cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BYV24P56.USD","IE00BMCWC346.EUR","SG9999004220.SGD","SG9999015986.USD","IE00BGHQDM52.EUR","BK1191","SG9999015945.SGD","IE00BVYPNQ40.USD","BK1593","IE00BVYPNP33.GBP","SG9999015952.SGD","LU2488822045.USD","SG9999015978.USD","00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618617106","title":"国产创新药持续发力，AD治疗领域将迎来新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2618617106","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618617106?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:29","pubTimestamp":1773019791,"startTime":"0","endTime":"0","summary":"据悉，继司普奇拜单抗之后多款国产药物也加速推进临床，并将迎来一波上市高潮。未来随着这些产品的获批上市，AD药物领域将迎来新的用药选择。随着多款新药的陆续上市，这不仅将打破国外药物垄断、降低患者用药成本，更将推动我国AD治疗的发展。未来，在政策支持与企业创新的双重驱动下，国内AD药物研发将持续突破，为全球特应性皮炎治疗贡献中国力量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091000479545971d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603091000479545971d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0634319403.HKD","LU2399975544.HKD","IE00B543WZ88.USD","LU0417516902.SGD","LU0348784397.USD","LU0348766576.USD","LU0348767384.USD","LU0417516571.SGD","LU0561508036.HKD","IE00B5MMRT66.SGD","02162","LU2778985437.USD","LU2476274720.SGD","LU0540923850.HKD","LU0348825331.USD","LU0348783233.USD","00867","LU1720050803.USD","IE00BPRC5H50.USD","LU1794554557.SGD","LU2488822045.USD","LU1961090484.USD","09926","06978","LU0417516738.SGD","BK1574","01276","LU2476274308.USD","LU0348735423.USD","LU0348827113.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617334504","title":"康哲药业：INHBE小核酸药物CMS-D008临床试验获批治疗超重或肥胖","url":"https://stock-news.laohu8.com/highlight/detail?id=2617334504","media":"财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617334504?lang=zh_cn&edition=full","pubTime":"2026-03-06 11:34","pubTimestamp":1772768040,"startTime":"0","endTime":"0","summary":"近日，康哲药业发布公告称，其自主研发的创新药INHBE小核酸药物CMS-D008于2026年3月4日获得中国国家药品监督管理局签发的药物临床试验批准通知书。该药物将用于超重或肥胖的临床试验。CMS-D008是一款皮下注射的siRNA药物，旨在通过靶向抑制肝脏的抑制素亚基βE基因表达，从而降低脂质堆积。全球超重和肥胖成年人的比例预计到2030年将达到50%，这为CMS-D008的市场前景提供了良好的基础。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-06/doc-inhpzkwr9288514.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-06/doc-inhpzkwr9288514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0553294199.USD","LU1894683264.USD","IE00BYV24P56.USD","IE00BVYPNQ40.USD","LU0545039389.USD","BK1191","LU2500361329.USD","IE00BVYPNP33.GBP","SG9999015978.USD","IE00BGHQDM52.EUR","BK4208","LU2637428348.USD","LU0949170772.SGD","BK4585","LU1894683348.USD","IE00BMCWC346.EUR","SG9999004220.SGD","BK1593","LU2488822045.USD","LU0738911758.USD","00867","SG9999015952.SGD","SG9999015945.SGD","BK4588","CMS","LU1003077747.HKD","LU0661504455.SGD","LU2346227817.USD","SG9999015986.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183212943","title":"康哲药业自主研发药物CMS-D008获准开展超重/肥胖适应症临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1183212943","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183212943?lang=zh_cn&edition=full","pubTime":"2026-03-04 19:08","pubTimestamp":1772622517,"startTime":"0","endTime":"0","summary":"康哲药业宣布，其自主研发的创新药CMS-D008已正式获得监管部门批准，将针对超重及肥胖适应症开展临床试验。该进展标志着公司在代谢疾病治疗领域取得重要突破，有望为体重管理提供新的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015945.SGD","BK1593","SG9999015986.USD","IE00BGHQDM52.EUR","SG9999015978.USD","BK1191","IE00BVYPNP33.GBP","SG9999015952.SGD","IE00BVYPNQ40.USD","SG9999004220.SGD","IE00BMCWC346.EUR","IE00BYV24P56.USD","00867","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616253165","title":"康哲药业(00867)：自主研发创新药INHBE小核酸药物CMS-D008获得超重或肥胖适应症药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616253165","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616253165?lang=zh_cn&edition=full","pubTime":"2026-03-04 18:58","pubTimestamp":1772621908,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，本集团自主研发的创新药INHBE小核酸药物CMS-D008注射液于2026年3月4日获得中国国家药品监督管理局签发的药物临床试验批准通知书。NMPA同意开展CMS-D008注射液用于超重或肥胖的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","SG9999015978.USD","BK1161","SG9999015945.SGD","BK4208","CMS","BK4588","IE00BVYPNP33.GBP","LU0949170772.SGD","SG9999015986.USD","LU1003077747.HKD","BK1593","06978","LU0738911758.USD","LU2488822045.USD","LU1894683348.USD","LU2500361329.USD","BK1191","00867","IE00BVYPNQ40.USD","SG9999015952.SGD","IE00BGHQDM52.EUR","LU0553294199.USD","LU1894683264.USD","LU2346227817.USD","IE00BMCWC346.EUR","LU0661504455.SGD","BK4585","LU2637428348.USD","SG9999004220.SGD","LU0545039389.USD","IE00BYV24P56.USD","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616531904","title":"康哲药业(00867.HK)拟3月16日举行董事会会议以审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2616531904","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616531904?lang=zh_cn&edition=full","pubTime":"2026-03-04 18:57","pubTimestamp":1772621821,"startTime":"0","endTime":"0","summary":"格隆汇3月4日丨康哲药业(00867.HK)公告，谨定于2026年3月16日(星期一)召开公司董事会会议，其中包括考虑及拟批准公司及其附属公司截至2025年12月31日止年度业绩，及考虑派发末期股息(如有)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260304/32044741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IE00BYV24P56.USD","IE00BMCWC346.EUR","SG9999004220.SGD","SG9999015986.USD","IE00BGHQDM52.EUR","BK1191","SG9999015945.SGD","IE00BVYPNQ40.USD","BK1593","IE00BVYPNP33.GBP","SG9999015952.SGD","LU2488822045.USD","SG9999015978.USD","00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616100763","title":"康哲药业盘中异动 早盘急速下挫5.08%报13.440港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616100763","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616100763?lang=zh_cn&edition=full","pubTime":"2026-03-03 10:06","pubTimestamp":1772503614,"startTime":"0","endTime":"0","summary":"2026年03月03日早盘10时06分，康哲药业股票出现异动，股价大幅跳水5.08%。截至发稿，该股报13.440港元/股，成交量300.2万股，换手率0.12%，振幅5.08%。资金方面，该股资金流入665.913万港元，流出3017.2万港元。最近的财报数据显示，该股实现营业收入43.88亿港元，净利润10.32亿港元，每股收益0.43港元，毛利31.71亿港元，市盈率18.74倍。康哲药业股票所在的药品行业中，整体跌幅为0.15%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030310065497a7bd67&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030310065497a7bd67&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999015952.SGD","IE00BYV24P56.USD","SG9999015945.SGD","00867","IE00BVYPNP33.GBP","LU2488822045.USD","SG9999015978.USD","SG9999015986.USD","IE00BGHQDM52.EUR","BK1593","IE00BVYPNQ40.USD","SG9999004220.SGD","BK1191","IE00BMCWC346.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616384262","title":"每日卖空追踪 | 康哲药业 03月02日卖空量成交23.7万股，卖空比例为5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616384262","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616384262?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:30","pubTimestamp":1772440218,"startTime":"0","endTime":"0","summary":"康哲药业北京时间03月02日，跌3.01%，卖空量成交23.7万股，较上一交易日减少68.77%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163211a4414d8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163211a4414d8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BYV24P56.USD","IE00BVYPNQ40.USD","00867","BK1593","SG9999015945.SGD","SG9999015952.SGD","SG9999015978.USD","SG9999015986.USD","IE00BVYPNP33.GBP","LU2488822045.USD","SG9999004220.SGD","IE00BMCWC346.EUR","IE00BGHQDM52.EUR","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cms.net.cn","stockEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.0699},{"period":"3month","weight":0.0134},{"period":"6month","weight":0.0338},{"period":"1year","weight":1.0168},{"period":"ytd","weight":0.1155}],"compareEarnings":[{"period":"1week","weight":0.0253},{"period":"1month","weight":-0.008},{"period":"3month","weight":-0.0183},{"period":"6month","weight":-0.0205},{"period":"1year","weight":0.2708},{"period":"ytd","weight":0.0048}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康哲药业控股有限公司是一家主要从事药品生产、营销、推广及销售业务的投资控股公司。该公司的产品包括波依定、优思弗、施图伦滴眼液、喜辽妥、艾蓓尔产品系列及Vmonalisa莫娜丽莎等。其主要在售产品覆盖心脑血管、消化、眼科、皮肤科及医美领域。该公司主要在中国国内和海外市场销售其产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.010984},{"month":2,"riseRate":0.6,"avgChangeRate":0.034663},{"month":3,"riseRate":0.4375,"avgChangeRate":-0.007428},{"month":4,"riseRate":0.5625,"avgChangeRate":0.032394},{"month":5,"riseRate":0.466667,"avgChangeRate":0.01146},{"month":6,"riseRate":0.666667,"avgChangeRate":0.005887},{"month":7,"riseRate":0.533333,"avgChangeRate":-0.008683},{"month":8,"riseRate":0.4,"avgChangeRate":0.021846},{"month":9,"riseRate":0.466667,"avgChangeRate":0.00566},{"month":10,"riseRate":0.5,"avgChangeRate":0.008421},{"month":11,"riseRate":0.5625,"avgChangeRate":0.054281},{"month":12,"riseRate":0.5625,"avgChangeRate":0.03433}],"exchange":"SEHK","name":"康哲药业","nameEN":"CMS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康哲药业(00867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康哲药业,00867,康哲药业股票,康哲药业股票老虎,康哲药业股票老虎国际,康哲药业行情,康哲药业股票行情,康哲药业股价,康哲药业股市,康哲药业股票价格,康哲药业股票交易,康哲药业股票购买,康哲药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康哲药业(00867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}